Compare Heron Therapeutics Inc (HRTX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Texas Instruments Incorporated — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Texas Instruments Incorporated trades at $283.85 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 4039× Heron Therapeutics Inc's market cap, and Texas Instruments Incorporated pays a 2.03% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TXN | |
|---|---|---|
Market Cap | $63.41M | $256.11B |
Sector | Health | Technology |
52-Week High | $1.49 | $332.35 |
52-Week Low | $0.32 | $153.33 |
Enterprise Value | $161.31M | $263.16B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.
Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
